| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
Prelude Therapeutics Inc
13G/A
PRLD · 74065P101
|
13.2% |
2/13/2026
Event 12/31/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.